As a privately owned German company, we own and operate 15 research-only clinics across 8 strategically selected countries on 4 continents, accelerating Proof-of-Concept trials with unmatched speed, precision, and an unwavering commitment to excellence. Inspired by the safety, professionalism, and perfection of F1 racing, ARENSIA challenges the traditional site model, delivering 50% greater study efficiency through complete dedication to research for innovative therapies in oncology, chronic diseases, and acute medical conditions.
Why sponsors put us on pole position
15
clinics under one SOP standard
190+
Inpatient beds
20+
therapeutic areas
+50%
fastest enrollment
−50%
less project cost
800
Employees
36
Drugs approved by FDAincluding data generated by ARENSIA
33
Drugs approved by EMAincluding data generated by ARENSIA
Health Authority and Ethics Committee reviewed in parallel.
Moldova
Pole position
2 weeks
Comitetul Național de Expertiză Etică a Studiului Clinic (CNEESC) · Agenția Medicamentului și Dispozitivelor Medicale (AMDM)
USA
4 weeks
U.S. Food and Drug Administration (FDA) · Institutional Review Board (IRB)
Georgia
4 weeks
ადგილობრივი ეთიკის კომიტეტი · საქართველოს ოკუპირებული ტერიტორიებიდან დევნილთა, შრომის, ჯანმრთელობისა და სოციალური დაცვის სამინისტრო
Ukraine
4 weeks
Державний експертний центр МОЗ України · Комісія з питань етики
Argentina
4 weeks
Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) · Comités de Ética en Investigación · Autoridad sanitaria provincial
Romania
8 weeks
Comisia Națională de Bioetică a Medicamentului și a Dispozitivelor Medicale (CNBMDM) · Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România (ANMDMR)
Bulgaria
8 weeks
Етична комисия за клинични изпитвания · Изпълнителна агенция по лекарствата
One block = one week · HA + EC reviewed in parallel.
Study types
ARENSIA performs the full range of complex exploratory, First-in-Human / First-in-Patient protocol designs — across one to multiple ARENSIA clinics.
Every ARENSIA clinic offers therapeutic expertise, novel modalities and integrated on-site diagnostics.
Oncology
Hematology
Cardiology
Respiratory
Gastroenterology
Hepatology
Nephrology
Metabolic
Endocrinology
Immuno-Inflammatory
Rheumatology
Dermatology
Neuropsychiatry
Infectious Diseases
Gynecology/Urology
Ophthalmology
Pain Medicine
Orthopaedics
Vascular surgery
Click a therapeutic area above to open its live patient enrollment — patients per clinic, per month.
Patients enrolled per clinic · per month
Types of novel IMPs tested
T cell engager / Trispecific / Bispecific
Combi of bispecific antibody + ADC
ADC with GR receptor + VISTA modulator
ADC Trastuzumab + Topoisomerase I inhibitor
siRNA / RNAi / Combi siRNA + mAb
RNA-based vaccine
cccDNA silencer
Factor XI mAbs
Relaxin Fc-fusion biologic
Anti OX-40 mAb
DPP1 inhibitor
Anti-IL4 / TSLP bispec mAb
Dual Glucagon / GLP-1 receptor agonist
NK3 receptor blocker
PDH kinase inhibitor
Bispecific capsid assembly modulator
MASP-3 binding mAb
Bispec nanobody molecule, TSLP/IL-13 inhibitor
Diagnostic capabilities
Non-Invasive
MRI, CT/PET-CT, PET-MRI, Ultrasound
Echocardiography
Fibroscan® / Elastography
DXA (Bone Density)
Ophthalmic Imaging
ECG / Holter Monitoring / Telemetry
Pulmonary Function Testing
Wearables & Remote Monitoring
EEG
Invasive
Tissue Biopsies
Bone Marrow Procedures
Lumbar Punctures
Endoscopy
Colonoscopy
Bronchoscopy
Right Heart Catheter
Synovial Fluid Sampling
Advanced Blood Work
Evidence behind the speed
ARENSIA’s capability is built on deep therapeutic expertise, a proven record in executing sophisticated protocols, and a body of science sponsors can independently verify — with patient safety, comfort, and trust embedded at the core of how every study is delivered.
Clinical track record
22 vs 5
patients per clinic: ARENSIA vs. other sites
Phase II · lung cancer
Each ARENSIA clinic recruited 22 patients. Other sites recruited 5 patients on average.
Umbrella study
4 IMPs — IV & oral + chemotherapy
Mandatory archival tissue; PD-L1 testing at screening
ALS-2200, A Novel Once-daily Nucleotide HCV Polymerase Inhibitor, Demonstrated Potent Antiviral Activity In Treatment-naïve Patients with Compensated Cirrhosis or Genotype 2-4 Chronic Hepatitis C
Improvement of Disease Activity and Reduction of Severe Flares Following Subcutaneous Administration of an IL-6 Monoclonal Antibody (mAb) in Subjects with Active Generalized Systemic Lupus Erythematosus (SLE)
Significant Clinical Improvement and Reduction of Severe Flares Following Administration of an IL-6 Monoclonal Antibody in Systemic Lupus Erythematosus (SLE) Subjects with High Disease Activity
In a 5-Day Monotherapy Trial, MK-8408 Demonstrates Potent Antiviral Activity and Improved Resistance Profile in HCV Patients with Genotypes 1, 2, and 3 Infections
AL-335, a once-daily pangenotypic nucleotide HCV polymerase inhibitor, demonstrates potent antiviral activity over 7 days in treatment-naïve genotype 1-4 patients
Bimekizumab, A Monoclonal Antibody That Inhibits both IL-17A and IL-17F, Produces A Profound Response in both Skin and Joints: Results of An Early-Phase, Proof-of-Concept Study in Psoriatic Arthritis